Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA.

Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16.

PMID:
29549161
2.

Analysis of growth factor signaling in genetically diverse breast cancer lines.

Niepel M, Hafner M, Pace EA, Chung M, Chai DH, Zhou L, Muhlich JL, Schoeberl B, Sorger PK.

BMC Biol. 2014 Mar 21;12:20. doi: 10.1186/1741-7007-12-20.

3.

Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines.

Niepel M, Hafner M, Pace EA, Chung M, Chai DH, Zhou L, Schoeberl B, Sorger PK.

Sci Signal. 2013 Sep 24;6(294):ra84. doi: 10.1126/scisignal.2004379.

4.

Delirium in advanced cancer leading to distress in patients and family caregivers.

Cohen MZ, Pace EA, Kaur G, Bruera E.

J Palliat Care. 2009 Autumn;25(3):164-71.

PMID:
19824277
5.

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB.

Sci Signal. 2009 Jun 30;2(77):ra31. doi: 10.1126/scisignal.2000352.

6.

Errors in symptom intensity self-assessment by patients receiving outpatient palliative care.

Garyali A, Palmer JL, Yennurajalingam S, Zhang T, Pace EA, Bruera E.

J Palliat Med. 2006 Oct;9(5):1059-65.

PMID:
17040143
7.

Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report.

Montoya M, Fossella F, Palmer JL, Kaur G, Pace EA, Yadav R, Simmonds M, Gillis T, Bruera E.

J Palliat Med. 2006 Apr;9(2):309-16.

PMID:
16629561
8.

The Edmonton Symptom Assessment System as a screening tool for depression and anxiety.

Vignaroli E, Pace EA, Willey J, Palmer JL, Zhang T, Bruera E.

J Palliat Med. 2006 Apr;9(2):296-303.

PMID:
16629559
9.

Inhibition of transcription factor NF-kappaB signaling proteins IKKbeta and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity.

Liang MC, Bardhan S, Pace EA, Rosman D, Beutler JA, Porco JA Jr, Gilmore TD.

Biochem Pharmacol. 2006 Feb 28;71(5):634-45. Epub 2005 Dec 19.

PMID:
16360644
10.

A compendium of signals and responses triggered by prodeath and prosurvival cytokines.

Gaudet S, Janes KA, Albeck JG, Pace EA, Lauffenburger DA, Sorger PK.

Mol Cell Proteomics. 2005 Oct;4(10):1569-90. Epub 2005 Jul 18.

12.

Angiogenesis inhibitor epoxyquinol a: total synthesis and inhibition of transcription factor NF-kappaB.

Li C, Bardhan S, Pace EA, Liang MC, Gilmore TD, Porco JA Jr.

Org Lett. 2002 Sep 19;4(19):3267-70.

PMID:
12227765
13.

Total synthesis of the NF-kappa B inhibitor (-)-cycloepoxydon: utilization of tartrate-mediated nucleophilic epoxidation.

Li C, Pace EA, Liang MC, Lobkovsky E, Gilmore TD, Porco JA Jr.

J Am Chem Soc. 2001 Nov 14;123(45):11308-9. No abstract available.

PMID:
11697981

Supplemental Content

Support Center